Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients33

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients24

Views

Views
October 20240
November 20240
December 20240
January 20258
February 20250
March 202516
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United Kingdom4
Lithuania2
United States2
 

Top cities views

Views
Charlotte2